On the Record · Pfizer
Pfizer acquisitions, on the record
The businesses Pfizer bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
ArenaWord for word“Our significant recent business development activities in 2022 include, among others: (i) the March 2022 acquisition of Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases; (ii) the October 2022 acquisition of GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease; and (iii) the October 2022 acquisition of Biohaven, the maker of Nurtec ODT/Vydura (rimegepant), an innovative therapy for both acute treatment of migraine and prevention of episodic migraine in adults.” 10-K for 2022 | acquisition | March 2022 | — |
MeridianWord for word“With the formation of the Consumer Healthcare JV in 2019, the spin-off of our former Upjohn Business in the fourth quarter of 2020 and the sale of our Meridian subsidiary in the fourth quarter of 2021, Pfizer transformed into a more focused, global leader in science-based innovative medicines and vaccines engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide.” 10-K for 2022 | divestiture | fourth quarter of 2021 | — |
SeagenWord for word“On December 14, 2023, we completed our acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.” 10-K for 2023 | acquisition | December 14, 2023 | — |
early-stage rare disease gene therapy portfolio (to Alexion)Word for word“In addition to the acquisition of Seagen, our significant recent business development activities in 2023 include, among others, the September 2023 divestiture of our early-stage rare disease gene therapy portfolio to Alexion.” 10-K for 2023 | divestiture | September 2023 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $18.37 billion | $6.37 billion |
| 2017-12-31 | $1 billion | $664 million |
| 2018-12-31 | $0 | — |
| 2019-12-31 | $10.86 billion | $5.41 billion |
| 2020-12-31 | $0 | $727 million |
| 2021-12-31 | $0 | $0 |
| 2022-12-31 | $23 billion | $2.92 billion |
| 2023-12-31 | $43.43 billion | $16.12 billion |
| 2024-12-31 | $0 | $1.02 billion |
| 2025-12-31 | $6.93 billion | $2.16 billion |
Deal filings since 2016
- 2023-12-14 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-03-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-11-20 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2020-06-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-07-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-12-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Pfizer’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023, 10-K for 2022) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.